dr. lopes on standard durations of checkpoint inhibition in metastatic lung cancer
Published 4 years ago • 98 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
4:36
efficacy and safety of checkpoint inhibitors in lung cancer
-
1:11
dr. lopes on the rationale to stop immunotherapy after 2 years in lung cancer
-
0:56
dr. lopes discusses steroid side effects in lung cancer management
-
4:47
immune checkpoint inhibitors in small-cell lung cancer
-
8:06
lung cancer: clinical insights into key research | gilberto lopes
-
8:16
immune checkpoint inhibitor combinations in non-small cell lung cancer
-
6:42
pseudoprogression with checkpoint inhibitors in non-small cell lung cancer
-
6:26
developing checkpoint inhibition in genitourinary cancers
-
2:30
dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc
-
12:33
introduction: checkpoint inhibition in non-small cell lung cancer
-
7:42
immune checkpoint inhibitors in squamous non-small cell lung cancer
-
7:54
immune checkpoint inhibitors in nsclc
-
7:55
emerging checkpoint inhibitors for lung cancer
-
1:06
checkpoint inhibitors advance standard of care for non-small cell lung cancers
-
1:16
dr. he on the potential of immune checkpoint inhibitors in gi cancers
-
1:16
dr. kim on the safety of immune checkpoint inhibition in surgical patients with lung cancer
-
7:34
sequencing checkpoint inhibitors in nsclc
-
9:40
checkpoint inhibitors for newly diagnosed stage 4 nsclc